全文获取类型
收费全文 | 8698篇 |
免费 | 553篇 |
国内免费 | 39篇 |
专业分类
耳鼻咽喉 | 79篇 |
儿科学 | 215篇 |
妇产科学 | 142篇 |
基础医学 | 958篇 |
口腔科学 | 148篇 |
临床医学 | 578篇 |
内科学 | 2584篇 |
皮肤病学 | 129篇 |
神经病学 | 842篇 |
特种医学 | 240篇 |
外科学 | 1204篇 |
综合类 | 64篇 |
一般理论 | 6篇 |
预防医学 | 554篇 |
眼科学 | 249篇 |
药学 | 570篇 |
1篇 | |
中国医学 | 33篇 |
肿瘤学 | 694篇 |
出版年
2023年 | 60篇 |
2022年 | 136篇 |
2021年 | 289篇 |
2020年 | 142篇 |
2019年 | 251篇 |
2018年 | 281篇 |
2017年 | 215篇 |
2016年 | 217篇 |
2015年 | 217篇 |
2014年 | 289篇 |
2013年 | 441篇 |
2012年 | 645篇 |
2011年 | 602篇 |
2010年 | 376篇 |
2009年 | 321篇 |
2008年 | 511篇 |
2007年 | 541篇 |
2006年 | 509篇 |
2005年 | 478篇 |
2004年 | 366篇 |
2003年 | 392篇 |
2002年 | 348篇 |
2001年 | 157篇 |
2000年 | 149篇 |
1999年 | 119篇 |
1998年 | 91篇 |
1997年 | 64篇 |
1996年 | 55篇 |
1995年 | 51篇 |
1994年 | 49篇 |
1993年 | 26篇 |
1992年 | 99篇 |
1991年 | 89篇 |
1990年 | 76篇 |
1989年 | 84篇 |
1988年 | 67篇 |
1987年 | 64篇 |
1986年 | 48篇 |
1985年 | 38篇 |
1984年 | 36篇 |
1983年 | 24篇 |
1982年 | 29篇 |
1981年 | 24篇 |
1980年 | 20篇 |
1979年 | 30篇 |
1978年 | 15篇 |
1977年 | 16篇 |
1976年 | 17篇 |
1975年 | 19篇 |
1974年 | 14篇 |
排序方式: 共有9290条查询结果,搜索用时 31 毫秒
111.
Clare W. Makumi Afsaneh Asgharian Jeffrey Ellis Soraya Shaikh Teri Jimenez Susan VanMeter 《The International journal of neuroscience》2016,126(1):30-38
Long-term safety of once-daily ropinirole extended/prolonged release (ropinirole XL/PR) was evaluated in subjects with early and advanced Parkinson's disease (PD) in this study, 101468/248. Subjects (n = 419) who completed one of three prior studies evaluating ropinirole XL/PR for the treatment of PD were enrolled in this open-label, multicenter, extension study, and were to be followed for up to 73 months. Ropinirole XL/PR was titrated/continued, and adjusted as appropriate during the maintenance phase (maximum 24 mg/d). Levodopa (L-dopa) and other nondopamine agonist PD medications were permitted. Safety outcomes that were investigated included frequency of adverse events (AEs). Subjects’ preference regarding once daily versus three times daily study medication regimens was also investigated in a subset of the study population. The median duration of ropinirole XL/PR exposure was 1275 d. Most subjects (87%) reported at least one AE, with the most common (≥ 10%) AEs being, back pain (14%), hallucinations (13%), somnolence (11%) and peripheral edema (11%). Twenty-five percent of subjects discontinued the study prematurely due to an AE during the treatment period. Long-term treatment with ropinirole XL/PR was not associated with any new or unexpected safety concerns in patients with early and advanced PD, and a majority of subjects preferred the once-daily dosing regimen. 相似文献
112.
Emanuele Angelucci Valeria Santini Anna Angela Di Tucci Giulia Quaresmini Carlo Finelli Antonio Volpe Giovanni Quarta Flavia Rivellini Grazia Sanpaolo Daniela Cilloni Flavia Salvi Giovanni Caocci Alfredo Molteni Daniele Vallisa Maria Teresa Voso Susanna Fenu Lorenza Borin Giancarlo Latte Giuliana Alimena Sergio Storti Alfonso Piciocchi Paola Fazi Marco Vignetti Sante Tura 《European journal of haematology》2014,92(6):527-536
113.
114.
Melatonin enhances neural stem cell differentiation and engraftment by increasing mitochondrial function
下载免费PDF全文
![点击此处可从《Journal of pineal research》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Miguel Mendivil‐Perez Viviana Soto‐Mercado Ana Guerra‐Librero Beatriz I. Fernandez‐Gil Javier Florido Ying‐Qiang Shen Miguel A. Tejada Vivian Capilla‐Gonzalez Iryna Rusanova José M. Garcia‐Verdugo Darío Acuña‐Castroviejo Luis Carlos López Carlos Velez‐Pardo Marlene Jimenez‐Del‐Rio José M. Ferrer Germaine Escames 《Journal of pineal research》2017,63(2)
Neural stem cells (NSCs) are regarded as a promising therapeutic approach to protecting and restoring damaged neurons in neurodegenerative diseases (NDs) such as Parkinson's disease and Alzheimer's disease (PD and AD, respectively). However, new research suggests that NSC differentiation is required to make this strategy effective. Several studies have demonstrated that melatonin increases mature neuronal markers, which reflects NSC differentiation into neurons. Nevertheless, the possible involvement of mitochondria in the effects of melatonin during NSC differentiation has not yet been fully established. We therefore tested the impact of melatonin on NSC proliferation and differentiation in an attempt to determine whether these actions depend on modulating mitochondrial activity. We measured proliferation and differentiation markers, mitochondrial structural and functional parameters as well as oxidative stress indicators and also evaluated cell transplant engraftment. This enabled us to show that melatonin (25 μM) induces NSC differentiation into oligodendrocytes and neurons. These effects depend on increased mitochondrial mass/DNA/complexes, mitochondrial respiration, and membrane potential as well as ATP synthesis in NSCs. It is also interesting to note that melatonin prevented oxidative stress caused by high levels of mitochondrial activity. Finally, we found that melatonin enriches NSC engraftment in the ND mouse model following transplantation. We concluded that a combined therapy involving transplantation of NSCs pretreated with pharmacological doses of melatonin could efficiently restore neuronal cell populations in PD and AD mouse models depending on mitochondrial activity promotion. 相似文献
115.
Scalp hypothermia as a preventative measure for chemotherapy‐induced alopecia: a review of controlled clinical trials
下载免费PDF全文
![点击此处可从《Journal of the European Academy of Dermatology and Venereology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
V.V. Shah T.C. Wikramanayake G.M. DelCanto C. van den Hurk S. Wu M.E. Lacouture J.J. Jimenez 《Journal of the European Academy of Dermatology and Venereology》2018,32(5):720-734
Chemotherapy‐induced alopecia (CIA) is a temporary, yet psychologically devastating form of hair loss that affects 65% of patients receiving cancer chemotherapy. In the 1970s, scalp hypothermia was introduced as a preventative measure against the development of CIA. Numerous studies provide evidence for the effectiveness of scalp cooling to prevent CIA, although results varied because of differences in chemotherapy regimen, cooling technique, mode of administration and patient factors. However, many of the existing studies are uncontrolled or consist of small sample sizes, and data from randomized, randomized studies are limited. To date, no clear guidelines have been established for optimum scalp cooling use as a treatment modality and its efficacy remain unknown. Nonetheless, scalp cooling remains the most widely utilized method for the prevention of CIA, and in December 2015, the United States Food and Drug Administration (FDA) cleared the DigniCap® Scalp Cooling System (Dignitana AB, Sweden) for marketing and the Orbis from Paxman® Coolers Ltd. received clearance in 2017. This literature review is one of the first to provide up‐to‐date review and side‐by‐side comparisons of controlled and randomized clinical trials (CCTs and RCTs) evaluating scalp hypothermia for the prevention of CIA. Our analyses of CCTs and RCTs to date show that scalp hypothermia is effective in reducing the occurrence rate of CIA, by 2.7‐fold in the CCTs and 3.9‐fold in the RCTs. These results suggest that scalp hypothermia represents an effective preventative measure for CIA, and provide guidance for management of anticipated alopecia following chemotherapy and for future investigations. 相似文献
116.
117.
118.
Licia Iaccarino Tiziana Ottone Valentina Alfonso Laura Cicconi Mariadomenica Divona Serena Lavorgna Serena Travaglini Aleandra Ferrantini Giulia Falconi Constance Baer Monica Usai Fabio Forghieri Adriano Venditti Maria Ilaria Del Principe William Arcese Maria Teresa Voso Torsten Haferlach Francesco Lo-Coco 《American journal of hematology》2019,94(10):1091-1097
Despite the high probability of cure of patients with acute promyelocytic leukemia (APL), mechanisms of relapse are still largely unclear. Mutational profiling at diagnosis and/or relapse may help to identify APL patients needing frequent molecular monitoring and early treatment intervention. Using an NGS approach including a 31 myeloid gene-panel, we tested BM samples of 44 APLs at the time of diagnosis, and of 31 at relapse. Mutations in PML and RARA genes were studied using a customized-NGS-RNA panel. Patients relapsing after ATRA-chemotherapy rarely had additional mutations (P = .009). In patients relapsing after ATRA/ATO, the PML gene was a preferential mutation target. We then evaluated the predictive value of mutations at APL diagnosis. A median of two mutations was detectable in 9/11 patients who later relapsed, vs one mutation in 21/33 patients who remained in CCR (P = .0032). This corresponded to a significantly lower risk of relapse in patients with one or less mutations (HR 0.046; 95% CI 0.011-0.197; P < .0001). NGS-analysis at the time of APL diagnosis may inform treatment decisions, including alternative treatments for cases with an unfavorable mutation profile. 相似文献
119.
José M. de la Torre Hernández Salvatore Brugaletta Joan A. Gómez Hospital José A. Baz Armando Pérez de Prado Ramón López Palop Belen Cid Tamara García Camarero Alejandro Diego Hipólito Gutiérrez José A. Fernández Diaz Juan Sanchis Fernando Alfonso Roberto Blanco Javier Botas Javier Navarro Cuartero José Moreu Francisco Bosa Antonio J. Domínguez 《Revista espa?ola de cardiología》2019,72(12):1005-1011
Background and objectivesPatients older than 75 years with ST-segment elevation myocardial infarction undergoing primary angioplasty in cardiogenic shock have high mortality. Identification of preprocedural predictors of short- and long-term mortality could be useful to guide decision-making and further interventions.MethodsWe analyzed a nationwide registry of primary angioplasty in the elderly (ESTROFA MI + 75) comprising 3576 patients. The characteristics and outcomes of the subgroup of patients in cardiogenic shock were analyzed to identify associated factors and prognostic predictors in order to derive a baseline risk prediction score for 1-year mortality. The score was validated in an independent cohort.ResultsA total of 332 patients were included. Baseline independent predictors of mortality were anterior myocardial infarction (HR 2.8, 95%CI, 1.4-6.0; P = .005), ejection fraction < 40% (HR 2.3, 95%CI, 1.14-4.50; P = .018), and time from symptom onset to angioplasty > 6 hours (HR 3.2, 95%CI, 1.6-7.5; P = .001). A score was designed that included these predictive factors (score “6-ANT-40”). Survival at 1 year was 54.5% for patients with score 0, 32.3% for score 1, 27.4% for score 2 and 17% for score 3 (P = .004, c-statistic 0.70). The score was validated in an independent cohort of 124 patients, showing 1-year survival rates of 64.5%, 40.0%, 28.9%, and 22.2%, respectively (P = .008, c-statistic 0.68).ConclusionsA preprocedural score based on 3 simple clinical variables (anterior location, ejection fraction < 40%, and delay time > 6 hours) may be used to estimate survival after primary angioplasty in elderly patients with cardiogenic shock and to guide preinterventional decision-making. 相似文献
120.